Antiplatelet Effects of Clopidogrel Vs Aspirin in Virologically Controlled HIV: A Randomized Controlled Trial

Area of Science:

• Cardiovascular Medicine
• Hematology
• Infectious Diseases

Background:

• Patients with Human Immunodeficiency Virus (HIV) show increased platelet activation.
• This platelet activation is linked to a higher risk of cardiovascular disease (CVD).
• Effective prevention strategies for CVD in HIV patients remain largely unknown.

Purpose of the Study:

• To investigate the effects of antiplatelet agents on platelet activation and endothelial inflammation in HIV patients.
• To compare the efficacy of clopidogrel and aspirin in modulating platelet phenotype and inflammatory responses.

Main Methods:

• A randomized trial involving 55 HIV-positive patients.
• Participants were assigned to receive clopidogrel, aspirin, or no treatment for 14 days.
• Platelet activation markers (P-selectin, PAC-1) and platelet-induced endothelial inflammation were assessed.

Main Results:

• Clopidogrel significantly reduced platelet activation compared to aspirin and no treatment.
• Platelet-induced proinflammatory gene expression in endothelial cells decreased with clopidogrel.
• No significant changes in these markers were observed in the aspirin or no-treatment groups.

Conclusions:

• Clopidogrel demonstrates potent antiplatelet and anti-inflammatory effects in HIV patients.
• These findings suggest a potential role for clopidogrel in managing cardiovascular risk in HIV.
• Clinical trials evaluating clopidogrel for CVD prevention in HIV are warranted.